After hours:
Chart Events
Performance Outlook
| Previous Close | 8.33 |
| Open | 8.69 |
| Bid | 8.75 x 2200 |
| Ask | 8.78 x 2900 |
| Day's Range | 8.69 - 8.97 |
| 52 Week Range | 1.75 - 11.00 |
| Volume | |
| Avg. Volume | 242,511 |
| Market Cap | 304.971M |
| Beta (5Y Monthly) | 1.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.92 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.34 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NBTX
Related Research
- Nanobiotix S.A.Daily – Vickers Top Buyers & Sellers for 08/17/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast monthArgus Research
GlobeNewswireNANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology
Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CESTPARIS and CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the oral presentation of the final readout on primary objectives from Study 102 Dose Expansion—the expansion part of a Phase 1 dos
- GlobeNewswire
NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer
Data presented at the 2023 Special Meeting on Pancreatic Cancer of the American Association for Cancer Research Preliminary data show local endoscopic injection of NBTXR3 followed by radiotherapy activation remains feasible with a tolerable safety profile in 15 patientsAs of the data cutoff, in 13 patients evaluable for efficacy, the study showed an injected tumor disease control rate of 92.3% (12/13)Preliminary results from the ongoing study showed median overall survival of 21 months from diag
- GlobeNewswire
NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3Upfront payment and first equity tranche received by Nanobiotix post H1 2023 from agreement with Janssen extends cash runway into the first quarter of 2024 and second quarter if the cash covenant of the European Investment Bank (EIB) was not applicableBolstering of clinical oncology development and commercialization capabilities with
